These medications mimic the bodys natural glucagon-like peptide-1 (GLP-1) hormone, which slows digestion, reduces hunger, and supports insulin regulation
Dual- and triple-receptor agonists acting via different receptors and postreceptor pathways seem attractive in view of potentially additive or synergistic effects in the treatment of T2D and obesity
If your aim is to reduce cardiovascular disease, restricting its use to a limited time only and for those with the highest BMIs doesnt make sense
In practice, metabolic therapy may be an adjunct to CPAP or oral appliances, rather than a wholesale replacement
It acts as a carrier molecule, shuttling fatty acid molecules across the mitochondrial membrane
A 0.5 mg weekly starting dose gives your body the gentlest possible introduction to receptor activation